Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Summary

This phase II trial is studying how well trastuzumab works in treating patients with metastatic or recurrent salivary gland cancer. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them

Timeline

Start

2005-07

Primary completion

2007-05

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual.”

Drugs

Indications